IDXX

$699.494.08%27.45

Idexx Laboratories Inc (IDXX)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$672.04

Offen:

$686.23

24-Stunden-Volumen:

331,107

Relatives Volumen:

0.45

Marktkapitalisierung:

$55.11B

Einnahmen:

$4.45B

Nettoeinkommen (Verlust:

$1.10B

KGV:

51.47

EPS:

$13.59

Netto-Cashflow:

$1.06B

1W Leistung:

+24.26%

1M Leistung:

+34.94%

6M Leistung:

+24.22%

1Y Leistung:

-3.13%

1-Tages-Spanne:

$681.70$700.23

1-Wochen-Bereich:

$540.61$681.50

52-Wochen-Spanne:

$500.61$769.98

Idexx Laboratories Inc Aktie (IDXX) Unternehmensprofil

Firmenname

Idexx Laboratories Inc

Sektor

Healthcare

Branche

Diagnostics & Research

Telefon

(207) 556-0300

Adresse

ONE IDEXX DRIVE, WESTBROOK, ME, USA

Mitarbeiter

11,000

@idexx

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

IDXX-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Idexx Laboratories Inc Aktie (IDXX) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-10-16	Eingeleitet	Goldman	Buy
2026-10-12	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2026-04-15	Eingeleitet	Citigroup	Neutral
2025-12-09	Eingeleitet	Barclays	Overweight
2025-10-31	Hochstufung	Stifel	Hold → Buy
2025-10-01	Eingeleitet	UBS	Neutral
2025-08-05	Bestätigt	BTIG Research	Buy
2025-07-01	Eingeleitet	Jefferies	Buy
2024-12-02	Eingeleitet	Leerink Partners	Outperform
2024-07-25	Eingeleitet	BTIG Research	Buy
2024-01-30	Herabstufung	Piper Sandler	Overweight → Neutral
2023-12-07	Eingeleitet	Exane BNP Paribas	Outperform
2023-12-04	Hochstufung	Cleveland Research	Neutral → Buy
2023-08-02	Herabstufung	Atlantic Equities	Overweight → Neutral
2022-07-25	Herabstufung	Stifel	Buy → Hold
2022-07-21	Hochstufung	Goldman	Neutral → Buy
2022-07-12	Eingeleitet	Piper Sandler	Overweight
2022-05-05	Herabstufung	BofA Securities	Buy → Neutral
2022-02-08	Eingeleitet	Atlantic Equities	Overweight
2021-11-18	Eingeleitet	Morgan Stanley	Overweight
2021-08-05	Resumed	Credit Suisse	Outperform
2021-07-12	Herabstufung	Guggenheim	Buy → Neutral
2021-02-17	Eingeleitet	Barclays	Overweight
2019-09-09	Eingeleitet	Goldman	Neutral
2019-05-23	Eingeleitet	Guggenheim	Buy
2018-11-02	Bestätigt	BofA/Merrill	Buy
2018-05-07	Bestätigt	Stifel	Buy
2018-01-16	Eingeleitet	Piper Jaffray	Overweight
2017-08-23	Hochstufung	BofA/Merrill	Neutral → Buy
2017-07-28	Hochstufung	CL King	Neutral → Buy
2017-02-03	Herabstufung	Feltl & Co.	Hold → Sell
2016-09-29	Resumed	BofA/Merrill	Neutral
2016-08-16	Bestätigt	Stifel	Buy
2016-08-03	Hochstufung	Northcoast	Sell → Neutral
2016-07-20	Bestätigt	Canaccord Genuity	Buy
2016-04-19	Bestätigt	Canaccord Genuity	Buy
2016-04-01	Eingeleitet	CL King	Neutral
2016-03-21	Bestätigt	Stifel	Buy
2016-02-04	Eingeleitet	Credit Suisse	Outperform
2015-10-29	Bestätigt	Stifel	Buy
2015-08-28	Herabstufung	Raymond James	Outperform → Mkt Perform
2015-08-13	Bestätigt	Stifel	Buy
2015-07-23	Bestätigt	Canaccord Genuity	Buy

Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	4,303.70	3,897.50	3,660.95	3,367.32	3,215.36
Cost of revenue USD (M)	1,644.12	1,518.58	1,470.98	1,362.99	1,325.93
Gross profit USD (M)	2,659.58	2,378.93	2,189.97	2,004.34	1,889.43
Research and development USD (M)	251.21	219.79	190.95	254.82	161.01
Operating expenses USD (M)	1,299.55	1,250.59	1,092.84	1,105.57	957.40
Operating income USD (M)	1,360.03	1,128.34	1,097.13	898.77	932.03
Income before tax USD (M)	1,324.19	1,109.83	1,061.18	859.97	902.65
Income tax expense USD (M)	264.73	221.96	216.13	180.88	157.81
Net income USD (M)	1,059.46	887.87	845.04	679.09	744.84
Basic EPS USD/shares	13.17	10.77	10.17	8.12	8.74
Diluted EPS USD/shares	13.08	10.67	10.06	8.03	8.60
Basic weighted shares shares (M)	80.43	82.47	83.07	83.62	85.20
Diluted weighted shares shares (M)	81.03	83.25	83.98	84.60	86.57

Idexx Laboratories Inc-Aktie (IDXX) Insiderhandel

Kingsley Lawrence DSep 04 '26
Director
Transaktion
Option Exercise
Kosten
$114.17
#Aktien
2,203
Wert ($)
251,517
#Aktien Gesamt
11,771
LAWRENCE D KINGSLEYSep 04 '26
Director
Transaktion
Proposed Sale
Kosten
$532.08
#Aktien
2,203
Wert ($)
1,172,178
#Aktien Gesamt
0
Kingsley Lawrence DSep 04 '26
Director
Transaktion
Sale
Kosten
$532.08
#Aktien
2,203
Wert ($)
1,172,178
#Aktien Gesamt
9,568
Emerson AndrewAug 20 '26
EVP, CFO and Treasurer
Transaktion
Option Exercise
Kosten
$178.26
#Aktien
265
Wert ($)
47,239
#Aktien Gesamt
4,507
FENNELL GEORGEJun 01 '26
Executive Vice President
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
639
Wert ($)
0
#Aktien Gesamt
10,717
Margaret Anne SzostakMay 20 '26
Director
Transaktion
Proposed Sale
Kosten
$553.58
#Aktien
1,344
Wert ($)
744,012
#Aktien Gesamt
0
JUNIUS DANIEL MMay 07 '26
Director
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
257
Wert ($)
0
#Aktien Gesamt
3,561
Peacock KarenMay 07 '26
Director
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
101
Wert ($)
0
#Aktien Gesamt
102
HOOLEY JOSEPH LMay 07 '26
Director
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
158
Wert ($)
0
#Aktien Gesamt
276
Vandebroek Sophie V.May 07 '26
Director
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
257
Wert ($)
0
#Aktien Gesamt
905

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Kingsley Lawrence D	Director	Sep 04 '26	Option Exercise	$114.17	2,203	251,517	11,771
LAWRENCE D KINGSLEY	Director	Sep 04 '26	Proposed Sale	$532.08	2,203	1,172,178	0
Kingsley Lawrence D	Director	Sep 04 '26	Sale	$532.08	2,203	1,172,178	9,568
Emerson Andrew	EVP, CFO and Treasurer	Aug 20 '26	Option Exercise	$178.26	265	47,239	4,507
FENNELL GEORGE	Executive Vice President	Jun 01 '26	Option Exercise	$0.00	639	0	10,717
Margaret Anne Szostak	Director	May 20 '26	Proposed Sale	$553.58	1,344	744,012	0
JUNIUS DANIEL M	Director	May 07 '26	Option Exercise	$0.00	257	0	3,561
Peacock Karen	Director	May 07 '26	Option Exercise	$0.00	101	0	102
HOOLEY JOSEPH L	Director	May 07 '26	Option Exercise	$0.00	158	0	276
Vandebroek Sophie V.	Director	May 07 '26	Option Exercise	$0.00	257	0	905

Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten

Nov 02, 2026

IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction - The Motley Fool

Nov 02, 2026

Charles River's Q3 Earnings on Deck: What's in Store for the Stock? - Zacks Investment Research

Nov 02, 2026

Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates - Zacks Investment Research

Nov 02, 2026

Oct 30, 2026

Cencora Gears Up to Report Q4 Results: How to Play the Stock? - Zacks Investment Research

Oct 30, 2026

Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock? - Zacks Investment Research

Oct 30, 2026

STERIS Set to Report Q2 Earnings: What's in the Cards for the Stock? - Zacks Investment Research

Oct 30, 2026

Oct 29, 2026